Canlyniadau Chwilio - Lars-Åke Levin

Use of Cost-Effectiveness Data in Priority Setting Decisions: Experiences from the National Guidelines for Heart Diseases in Sweden gan Nathalie Eckard, Magnus Janzon, Lars-Åke Levin

Connect to this object online.

Including Both Costs and Effects - The Challenge of Using Cost-Effectiveness Data in National-Level Policy-Making: A Response to Recent Commentaries gan Nathalie Eckard, Magnus Janzon, Lars-Åke Levin

Connect to this object online.

The impact of service and hearing dogs on health-related quality of life and activity level: a Swedish longitudinal intervention study gan Martina Lundqvist, Lars-Åke Levin, Kerstin Roback, Jenny Alwin

Connect to this object online.

A Cost-utility Analysis of Calcipotriol/Betamethasone Dipropionate Aerosol Foam versus Ointment for the Topical Treatment of Psoriasis Vulgaris in Sweden gan Albert Duvetorp, Lars-Åke Levin, Emma Engerstedt Mattsson, Lasse Ryttig

Connect to this object online.

A pain relieving reimbursement program? Effects of a value-based reimbursement program on patient reported outcome measures gan Thérèse Eriksson, Hans Tropp, Ann-Britt Wiréhn, Lars-Åke Levin

Connect to this object online.

Correction to: A pain relieving reimbursement program? Effects of a value-based reimbursement program on patient reported outcome measures gan Thérèse Eriksson, Hans Tropp, Ann-Britt Wiréhn, Lars-Åke Levin

Connect to this object online.

Patient benefit of dog-assisted interventions in health care: a systematic review gan Martina Lundqvist, Per Carlsson, Rune Sjödahl, Elvar Theodorsson, Lars-Åke Levin

Connect to this object online.

Approaches to manage 'affordability' of high budget impact medicines in key EU countries gan Mathias Flume, Marc Bardou, Stefano Capri, Oriol Sola-Morales, David Cunningham, Lars-Ake Levin, Maarten J. Postma, Nicolas Touchot

Connect to this object online.